NovoFocus CR offers comprehensive gene coverage for hereditary cancer screening by analysing whole exon regions of genes recommended by international guidelines in one sample and one test. This is particularly important for individuals who carry hereditary pathogenic variants and are at increased risk of developing cancer, as early detection allows for personalised screening programmes, preventive measures and proactive treatment to maximise health outcomes.
System that meets the requirements of national and international standards, including CAP accreditation
No limit on sample number
Industry-leading turnaround time
Guaranteed Q30 ≥ 85%
Publication-ready results and bioinformatic consultants available for data interpretation
NovoFocus™ CR contains 106 genes associated with hereditary cancers. The genes are carefully selected with the potential risks of developing one or more of the following hereditary tumors.
(*OMIM Database and NCCN Guidelines)
The field is required.